EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach

Amanda Eckstrom iD, Anudishi Tyagi, Maryam Siddiqui, Jenny Borgman, Jieming Zeng, Adishwar Rao, Abhishek Maiti, Venkata Lokesh Battula

Cancers · 29.09.2025 · 17 (19) · 3166

DOI: 10.3390/cancers17193166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 29.09.2025. Verfasst von Amanda Eckstrom und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CytoMed Therapeutics, CytoMed Therapeutics Limited, National Institutes of Health/National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Venetoclax-based combination therapies have provided treatment options for patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. However, venetoclax resistance is common, and for such patients, the prognosis is dismal, and treatment approaches with different mechanisms of action are urgently needed. γδ T cells are a promising candidate owing to their good safety profile and cytotoxic effects in various types of cancers but are mostly unstudied in AML.

Methods

Here we used flow cytometry to profile the subtype and memory phenotype of peripheral blood γδ T cells in AML patients and investigate the feasibility of using donor-derived Vγ9Vδ2 T cells to treat AML as both a single agent and in combination with venetoclax. Additionally, we used bioluminescence imaging to examine the effect of donor-derived Vγ9Vδ2 T cells on AML xenograft models alone and in combination with venetoclax.

Results

We observed that Vδ2 T cells were less abundant and the TEMRA (terminally differentiated effector memory) phenotype was more prevalent as compared with that of healthy donors, suggesting that replenishing patients with Vδ2 T cells may be an effective treatment option. We found that donor-derived Vγ9Vδ2 T cells that Vγ9Vδ2 T cells efficiently induced apoptosis in AML cells from eight cell lines and three primary cultures in an effector-to-target cell ratio-dependent manner. Moreover, Vγ9Vδ2 T cells showed potent cytotoxicity against the venetoclax-resistant OCI-AML3 cell line and remained potent in the presence of venetoclax. Treatment with Vγ9Vδ2 T cells significantly extended survival in two AML xenograft models established with the aggressive Molm-13 and the venetoclax-resistant OCI-AML3 cell lines. An additive effect of venetoclax and Vγ9Vδ2 T cells was observed in the latter model.

Conclusions

Overall, these findings suggest Vγ9Vδ2 T cells as a promising “off-the-shelf” immunotherapy approach for AML patients, especially for patients with venetoclax-resistant disease.

Schlagwörter

Stichwörter der Autor:innen

Vγ9Vδ2 T cellsacute myeloid leukemiaadoptive cell therapyvenetoclax

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Internal Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • CytoMed Therapeutics Limited, Singapore 149544, Singapore.
  • Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ORCID-Profile: Amanda Eckstrom

Förderung

  • CytoMed Therapeutics
  • CytoMed Therapeutics Limited
  • National Institutes of Health/National Cancer Institute

Zitieren

APA

Eckstrom, A., Tyagi, A., Siddiqui, M., Borgman, J., Zeng, J., Rao, A., Maiti, A., & Battula, V. L. (2025). Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach. Cancers, 17(19), 3166. https://doi.org/10.3390/cancers17193166

Vancouver

Eckstrom A, Tyagi A, Siddiqui M, Borgman J, Zeng J, Rao A, et al. Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach. Cancers. 2025;17(19):3166. doi:10.3390/cancers17193166

BibTeX
@article{Eckstrom2025,
  author = {Eckstrom, Amanda and Tyagi, Anudishi and Siddiqui, Maryam and Borgman, Jenny and Zeng, Jieming and Rao, Adishwar and Maiti, Abhishek and Battula, Venkata Lokesh},
  title = {Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {19},
  pages = {3166},
  doi = {10.3390/cancers17193166}
}
Kostenlos starten →